medigraphic.com

2014, Number 2

<< Back Next >>

Rev Cuba Endoc 2014; 25 (2)

Results of somatotropinoma surgery through endoscopic transnasal approach using the neuronavigation technique

Cabrera GM, Turcios TS, Fernández LA, Hidalgo GA, Más GM

Language: Spanish
References: 24
Page: 66-75
PDF size: 218.97 Kb.


ABSTRACT

Introduction: treatment of choice for growth hormone-producing hypophysial tumors is surgery. The recurrence percentage is high but, to a great extent, is related to the surgeon´s experience, the surgical technique and the multidisciplinary work. Since 2011, a multidisciplinary team was created to guide the behavior and the follow-up of these patients who would be operated on by using the endoscopic technique based on the neuronavigation.
Objective: to describe the results of the growth hormone-producing hypophysial adenomas surgery by using the neuronavigation technique.
Methods: a descriptive study that included checking of the medical records of 18 patients diagnosed with growth hormone-producing hypophysial tumors and referred for endoscopic surgical treatment through neuronavigation. The analyzed variables were age, sex, tolerance test for glucose to measure growth hormone before and 7 days after surgery, the characteristics of the tumor, the postsurgical complications and the progress.
Results: of this group of 18 patients, 66.6 % were males 33.4 % had tumors growing into the floor of the Turkish saddle and the postsurgical complications were minimal: 16.7 % presented with transient diabetes insipidus and the same percentage had a cerebrospinal fluid fistula. Biochemical remission was detected in 55 % of patients one week after the surgery.
Conclusions: growth hormone-producing hypophysial tumors surgery using the endoscopic technique with neuronavigator provides advantages for patients, with satisfactory recovery from the clinical and biochemical viewpoint as well as low frequency of complications.


REFERENCES

  1. Garduño AA, Zamarripa R, Vergara A, Guillén MA, Escudero I. Análisis de la calidad de vida en pacientes con acromegalia en el Centro Médico Nacional 20 de Noviembre, ISSSTE. Rev Endocrinol Nutr. 2011;19(3):97-101.

  2. Colao A, Ferrone D, Marzullo P, Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis and management. Endocr Rev. 2004;25(1):102-52.

  3. Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA, Beckers A. High Prevalence of Pituitary Adenomas: A Cross-Sectional Study in the Province of Liège, Belgium. J Clin Endocrinol Metab. 2006;91(12):4769-75.

  4. Cordero RA, Barkan AL. Current diagnosis of acromegaly. Rev Endocr Metab Disord. 2008;9(1):13-9.

  5. Manavela MP, Juri A, Danilowicz K, Bruno OD. Enfoque terapéutico en 154 pacientes con acromegalia. Medicina (Buenos Aires). 2010;70(9):328-32.

  6. Cook DM, Ezzat S, Katznelson L, Kleinberg DL, Laws ER Jr., Nippoldt TB, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of Acromegaly. Endocr Pract. 2004;10(3):213-25.

  7. Carrasco C, Veliz J, Rojas D, Wohllk N. Resultados terapéuticos en pacientes acromegálicos: es tiempo de intervenir. Rev Méd Chile. 2006;134(1):989-96.

  8. Carmichael JD, Bonert VS .Medical therapy: options and uses. Rev Endocr Metab Disord. 2008;(1)9:71-81.

  9. López O, González JL, Morales O, Nedel L. Cirugía transesfenoidal: primera opción de tratamiento para adenomas hipofisarios secretores de GH. Rev Cubana Endocrinol [serie en Internet]. 2004 [citado 14 de abril de 2014];(15)3. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1561- 29532004000300003&lng=es&nrm=iso&tlng=es

  10. Laws ER. Surgery for acromegaly: evolution of the techniques and outcomes. Rev Endocr Metab Disord. 2008;9(1):67-70.

  11. Armengota M, Gallego JM, Gómez MJ, Barcia JA, Basterrae J, Barciab C. Abordajes transesfenoidales endoscópicos de los adenomas hipofisarios: una revisión crítica de nuestra experiencia. Acta Otorrinolaringol Esp. 2011;62(1):25-30.

  12. Orme SM, Mcnally RJ, Cartwright RA, Belchetz PE. Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab. 1998;83(8):2730-4.

  13. Swearingen B, Barker FG, Katznelson L, Biller B, Grinspoon S, Kilibanshi A, et al. Long term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab. 1998;83:3419-26.

  14. Rojas-Zalazar D, Mura J, Cataldo C, Wohllk N. Manejo multidisciplinario de la acromegalia. Rev Chil Neuro-Psiquiat. 2011;49(1):37-46.

  15. Bengtsoon BA, Eden S, Ernest I, Oden A, Sjogren B. Epidemiology and long term survival in acromegaly: a study of 166 cases diagnosed between 1955 and 1984. Acta Med Scand. 1988;223:327-35.

  16. Rajasoorya C, Holdaway IM, Wrightson P, Scott DJ, Ibbertson HK. Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol (Oxf). 1994;41(1):95-102.

  17. Mestron A, Webb SM, Astorga R, Benito P, Catala M, Gaztambide S, et al. Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Español de Acromegalia, REA). Eur J Endocrinol. 1993 Oct;151(4):439-6.

  18. Campos E, Tello T, Joya J, Vergara A, Ortega MR, Guillén MA. Características clínicas y bioquímicas de los pacientes con acromegalia del Centro Médico Nacional "20 de Noviembre". Revista de Endocrinología y Nutrición. 2010;18(2):78-83.

  19. Ribeiro-Oliveira A, Faje A, Barkan A. Limited utility of oral glucose tolerance test in biochemically active acromegaly. Eur J Endocrinol. 2011;164(1):17-22.

  20. Cozzi R, Montini M, Attanasio R, Albizzi M, Lasio G, Lodrini S, et al. Primary treatment of acromegaly with octreotide LAR: a long term (Up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage. J Clin Endocrinol Metab. 2006;91:1397-403.

  21. Mercado M, Borges F, Bouterfa H, Chang TC, Chervin A, Farrall AJ, et al; Study Group. A prospective, multicenter study to investigate the efficacy, safety and tolerability of octreotide LAR en the primary therapy of patients with acromegaly. Clin Endocrinol. 2007;66(6):859-68.

  22. Colao A, Ferone D, Marzullo P, Cappabianca P, Cirillo S, Boerlin V, et al. Long term effects of depot long acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. J Clin Endocrinol Metab. 2001;86(6):2779-86.

  23. Melmed S. Acromegaly. N Engl J Med. 2006;355(24):2558-73.

  24. Isidro ML, Castro JA, Penin MA, Armenta J, Cordido J. ¿Es siempre la cirugía el tratamiento de elección en la acromegalia? Endocrinol Nutr. 2007;54(3):145-50.




2020     |     www.medigraphic.com